Abstract:Background: Retinoblastoma, the most common pediatric intraocular malignancy, can develop during embryogenesis, with most children being diagnosed at 3–4 years of age. Multimodal therapies are typically associated with high levels of cytotoxicity and side effects. Therefore, the development of novel treatments with minimal side effects is crucial. Magnolol has a significant anti-tumor effect on various cancers. However, its antitumor effect on retinoblastoma remains unclear. Purpose: The study aimed to determine the effects of magnolol on the regulation of EMT, migration, invasion, and cancer progression in retinoblastoma and the modulation of miR-200c-3p expression and the Wnt/ zinc finger E-box binding homeobox 1 (ZEB1)/E-cadherin axis in vivo and in vitro . Methods: The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (MTT) assay was used to evaluate magnolol-induced cell toxicity in the Y79 retinoblastoma cell line. Flow cytometry and immunostaining assays were performed to investigate the magnolol-regulated mitochondrial membrane potential and the intracellular and mitochondrial reactive oxygen species levels in Y79 retinoblastoma cells. Orthotopic and subcutaneous xenograft experiments were performed in eight-week-old male null mice to study retinoblastoma progression and metastasis. In situ hybridization and quantitative reverse transcription polymerase chain reaction (RT-qPCR) assays were performed to evaluate the level of the anti-cancer miRNA miR-200c-3p. The mRNA and protein levels of E-cadherin, β-catenin, α-smooth muscle actin (α-SMA), fibronectin-1, and ZEB1 were analyzed using RT-qPCR, immunoblot, immunocytochemistry, and immunohistochemistry assays in vitro and in vivo. Results: Magnolol increased E-cadherin levels and reduced the activation of the EMT signaling pathway, EMT, tumor growth, metastasis, and cancer progression in the Y79 retinoblastoma cell line as well as in the orthotopic and subcutaneous xenograft animal models. Furthermore, magnolol increased the expression of miR-200c-3p. Our results demonstrate that miRNA-200c-3p inhibits EMT progression through the Wnt16/β-catenin/ZEB1/E-cadherin axis, and the ZEB1 silencing response shows that miR-200c-3p regulates ZEB1-mediated EMT in retinoblastoma. Conclusion: Magnolol has an antitumor effect by increasing E-cadherin and miRNA-200c-3p expression to regulate ZEB1-mediated EMT and cancer progression in retinoblastoma. The anti-tumor effect of magnolol by increasing E-cadherin and miRNA-200c-3p expression to regulate ZEB1-mediated EMT and cancer progression in retinoblastoma has been elucidated for the first time.

Magnolol Suppresses the Proliferation and Invasion of Cholangiocarcinoma Cells Via Inhibiting the NF-κB Signaling Pathway.

Magnolol Suppresses Pancreatic Cancer Development in Vivo and in Vitro Via Negatively Regulating TGF-β/Smad Signaling

Apoptosis Induction and ERK/NF‐κB Inactivation Are Associated with Magnolol‐inhibited Tumor Progression in Hepatocellular Carcinoma in Vivo

Magnolol Inhibits Growth of Gallbladder Cancer Cells Through the P53 Pathway

Magnolol's Therapeutic Efficacy and Immunomodulatory Effects in Oral Squamous Cell Carcinoma

Magnolol Induces Apoptosis and Suppresses Immune Evasion in Non-small Cell Lung Cancer Xenograft Models

Magnolol Exerts Anticancer Activity in Hepatocellular Carcinoma Cells Through Regulating Endoplasmic Reticulum Stress-Mediated Apoptotic Signaling

Unveiling Nature's Potential Weapon: Magnolol's Role in Combating Bladder Cancer by upregulating the miR-124 and inactivating PKC-δ/ERK Axis

Induction of Apoptosis, Inhibition of MCL-1, and VEGF-A Expression Are Associated with the Anti-Cancer Efficacy of Magnolol Combined with Regorafenib in Hepatocellular Carcinoma

2-O-Methylmagnolol, a Magnolol Derivative, Suppresses Hepatocellular Carcinoma Progression via Inhibiting Class I Histone Deacetylase Expression

Magnolol inhibits cancer stemness and IL-6/Stat3 signaling in oral carcinomas

Magnolol Promotes the Autophagy of Esophageal Carcinoma Cells by Upregulating HACE1 Gene Expression.

The Natural Compound Magnolol Inhibits Invasion and Exhibits Potential in Human Breast Cancer Therapy

MLN2238 exerts its anti-tumor effects <i>via</i> regulating ROS/JNK/mitochondrial signaling pathways in intrahepatic cholangiocarcinoma

The In Vivo Radiosensitizing Effect of Magnolol on Tumor Growth of Hepatocellular Carcinoma.

Induction of Apoptosis by Magnolol Via the Mitochondrial Pathway and Cell Cycle Arrest in Renal Carcinoma Cells.

Magnolol: A Neolignan from the Magnolia Family for the Prevention and Treatment of Cancer

Magnolol Enhances the Therapeutic Effects of TRAIL through DR5 Upregulation and Downregulation of c-FLIP and Mcl-1 Proteins in Cancer Cells

Discovery and Synthesis of Novel Magnolol Derivatives with Potent Anticancer Activity in Non-Small Cell Lung Cancer.

Magnolol regulates miR-200c-3p to inhibit epithelial–mesenchymal transition and retinoblastoma progression by modulating the ZEB1/E-cadherin axis in vitro and in vivo

Synergistic effects of autophagy/mitophagy inhibitors and magnolol promote apoptosis and antitumor efficacy